fluorodopa f 18 has been researched along with Parkinson Disease, Secondary in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (13.64) | 18.7374 |
| 1990's | 13 (59.09) | 18.2507 |
| 2000's | 2 (9.09) | 29.6817 |
| 2010's | 4 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Djaldetti, R; Greenbaum, L; Lorberboym, M; Poewe, W; Rigbi, A; Roditi, Y; Scherfler, C; Steinmetz, A | 1 |
| Harada, N; Kakiuchi, T; Kanazawa, M; Muramatsu, S; Ohba, H; Tsukada, H | 1 |
| Bahri, MA; Becker, G; Garraux, G; Hustadt, F; Lemaire, C; Luxen, A; Michel, A; Plenevaux, A | 1 |
| Bakay, RA; Deogaonkar, M; Lieu, CA; Subramanian, T | 1 |
| Cordes, M; Poewe, W | 1 |
| Calne, DB; Langston, JW; Schulzer, M; Snow, BJ; Tetrud, JW; Vingerhoets, FJ | 1 |
| Adams, R; Bankiewicz, K; Comi, G; Di Chiro, G; Kopin, IJ; Miletich, RS; Plunkett, R | 1 |
| Calne, DB; Nygaard, TG; Snow, BJ; Takahashi, H | 1 |
| Bhatt, MH; Calne, DB; Nakamura, K; Nomoto, M; Okada, A; Osame, M; Snow, BJ | 1 |
| Brooks, DJ; Burn, DJ | 1 |
| Fukui, M; Miyagi, Y; Morioka, T; Otsuka, M | 1 |
| Aigner, TA; Chan, GL; Doudet, DJ; Holden, JE; McGeer, EG; Ruth, TJ; Wyatt, RJ | 1 |
| Barlogie, B; Dhodapkar, M; Eidelberg, D; Harik, SI; Rudnicki, SA | 1 |
| Aigner, TG; Doudet, D; Fernández-Ruiz, J | 1 |
| Bottlaender, M; Condé, F; Coulon, C; Dollé, F; Frouin, V; Fuseau, C; Grégoire, MC; Hantraye, P; Hinnen, F; Poyot, T | 1 |
| Broussolle, E; Guillouet, S; Thobois, S | 1 |
| Aigner, TG; Cohen, RM; Doudet, DJ; McLellan, CA | 1 |
| Brooks, DJ | 1 |
| Barrio, JR; Hoffman, JM; Huang, SC; Mazziotta, JC; Melega, WP; Phelps, ME; Satyamurthy, N; Schneider, JS; Yu, DC | 1 |
| Martin, WR; Myers, JA; Rosenberg, NL | 1 |
| Adam, MJ; Calne, DB; Chu, NS; Clark, C; Huang, CC; Li, D; Okada, J; Peppard, RF; Ruth, TJ; Wolters, EC | 1 |
| Burns, RS; Chirakal, R; Chiueh, CC; Firnau, G; Garnett, ES; Kopin, IJ; Nahmias, C | 1 |
1 review(s) available for fluorodopa f 18 and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.
Topics: Aging; Animals; Antiparkinson Agents; Basal Ganglia; Brain Tissue Transplantation; Cell Transplantation; Cerebrovascular Circulation; Diagnosis, Differential; Dihydroxyphenylalanine; Dopamine Agonists; Electric Stimulation Therapy; Fetal Tissue Transplantation; Forecasting; Genetic Predisposition to Disease; Humans; Iatrogenic Disease; Imagination; Ligands; Mesencephalon; Motor Activity; Nerve Degeneration; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Neurotransmitter Agents; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders; Radiopharmaceuticals; Rats; Receptors, Dopamine; Risk; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Tremor | 2001 |
21 other study(ies) available for fluorodopa f 18 and Parkinson Disease, Secondary
| Article | Year |
|---|---|
The role of exposure to pesticides in the etiology of Parkinson's disease: a
Topics: Aged; Austria; Cohort Studies; Dihydroxyphenylalanine; Environmental Exposure; Female; Humans; Israel; Male; Middle Aged; Neostriatum; Parkinson Disease; Parkinson Disease, Secondary; Pesticides; Positron-Emission Tomography | 2019 |
Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
Topics: Animals; Brain; Carbidopa; Dihydroxyphenylalanine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Enzyme Inhibitors; Levodopa; Macaca fascicularis; MPTP Poisoning; Parkinson Disease, Secondary; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Presynaptic; Tyrosine | 2016 |
Comparative assessment of 6-[
Topics: Animals; Apomorphine; Aromatic-L-Amino-Acid Decarboxylases; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Fluorine Radioisotopes; Image Processing, Computer-Assisted; Male; Neostriatum; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Receptors, Presynaptic; Stereotyped Behavior; Tyrosine | 2017 |
Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Carotid Arteries; Conditioning, Operant; Corpus Striatum; Dihydroxyphenylalanine; Dopamine Agents; Dyskinesia, Drug-Induced; Dystonia; Female; Injections, Intravenous; Levodopa; Macaca mulatta; MPTP Poisoning; Parkinson Disease, Secondary; Psychomotor Performance; Radionuclide Imaging; Radiopharmaceuticals; Substantia Nigra | 2011 |
[Presynaptic nigrostriatal function in Parkinson disease and Parkinson-plus syndromes. Comparative studies using positron emission tomography with L-6-(18F)fluorodopa].
Topics: Adult; Aged; Aged, 80 and over; Corpus Striatum; Dihydroxyphenylalanine; Dominance, Cerebral; Dopamine; Female; Fluorine Radioisotopes; Humans; Kinetics; Male; Middle Aged; Neural Pathways; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine; Substantia Nigra; Synaptic Transmission; Tomography, Emission-Computed | 1994 |
Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Aged, 80 and over; Corpus Striatum; Dihydroxyphenylalanine; Disease Progression; Dopamine; Female; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Substantia Nigra; Syndrome; Tomography, Emission-Computed | 1994 |
6-[18F]fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys.
Topics: Animals; Catechol O-Methyltransferase Inhibitors; Catechols; Dihydroxyphenylalanine; Fluorine Radioisotopes; Macaca mulatta; Parkinson Disease, Secondary; Pentanones; Radioligand Assay; Reference Values; Tomography, Emission-Computed | 1993 |
Clinical heterogeneity of dopa-responsive dystonia: PET observations.
Topics: Adult; Aged; Corpus Striatum; Diagnosis, Differential; Dihydroxyphenylalanine; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine; Tomography, Emission-Computed | 1993 |
PET scan study on the dopaminergic system in a Japanese patient with hereditary progressive dystonia (Segawa's disease). Case report.
Topics: Corpus Striatum; Dihydroxyphenylalanine; Dystonia; Female; Humans; Japan; Levodopa; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Tomography, Emission-Computed | 1993 |
Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study.
Topics: Adult; Aged; Animals; Caudate Nucleus; Dihydroxyphenylalanine; Dopamine; Dopamine Antagonists; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Putamen; Substantia Nigra; Tomography, Emission-Computed | 1993 |
Striatal glucose metabolism and [18F]fluorodopa uptake in a patient with tumor-induced hemiparkinsonism.
Topics: Blood Glucose; Corpus Striatum; Dihydroxyphenylalanine; Dominance, Cerebral; Dopamine; Electromyography; Female; Humans; Meningeal Neoplasms; Meningioma; Middle Aged; Neurologic Examination; Parkinson Disease, Secondary; Radionuclide Imaging | 1993 |
6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Macaca fascicularis; Macaca mulatta; Parkinson Disease, Secondary; Reference Values; Tomography, Emission-Computed | 1998 |
Nervous system dysfunction in Waldenström's macroglobulinemia: response to treatment.
Topics: Antibodies, Monoclonal; Bone Marrow Transplantation; Dihydroxyphenylalanine; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Immunoglobulin M; Male; Middle Aged; Myelin-Associated Glycoprotein; Neural Conduction; Parkinson Disease, Secondary; Peripheral Nervous System Diseases; Tomography, Emission-Computed; Waldenstrom Macroglobulinemia | 1998 |
Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys.
Topics: Animals; Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine Agents; Fluorine Radioisotopes; Levodopa; Macaca mulatta; Male; Memory; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary; Psychomotor Performance; Space Perception | 1999 |
Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Carbon Radioisotopes; Carrier Proteins; Caudate Nucleus; Cerebellum; Corpus Striatum; Dihydroxyphenylalanine; Dopamine Plasma Membrane Transport Proteins; Fluorine Radioisotopes; Kinetics; Ligands; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Nortropanes; Papio; Parkinson Disease, Secondary; Putamen; Reserpine; Substantia Nigra; Tomography, Emission-Computed; Tyrosine 3-Monooxygenase | 2001 |
Positron emission tomography with 18F-dopa: interpretation and biological correlates in nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Cerebral Cortex; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Homovanillic Acid; Hydroxyindoleacetic Acid; Macaca mulatta; Methoxyhydroxyphenylglycol; Parkinson Disease, Secondary; Receptors, Dopamine; Tomography, Emission-Computed | 1992 |
Detection of preclinical Parkinson's disease with PET.
Topics: Adult; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; Diseases in Twins; Dopamine; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Putamen; Reference Values; Tomography, Emission-Computed; Tremor | 1991 |
6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Dihydroxyphenylalanine; Dopamine; Fluorescent Dyes; Fluorine Radioisotopes; Macaca nemestrina; Male; Parkinson Disease; Parkinson Disease, Secondary; Putamen; Tomography, Emission-Computed | 1990 |
Cyanide-induced parkinsonism: clinical, MRI, and 6-fluorodopa PET studies.
Topics: Cyanides; Dihydroxyphenylalanine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease, Secondary; Potassium Cyanide; Suicide, Attempted; Tomography, Emission-Computed | 1989 |
Positron emission tomography in manganese intoxication.
Topics: Adult; Brain; Chronic Disease; Dihydroxyphenylalanine; Humans; Magnetic Resonance Imaging; Manganese Poisoning; Parkinson Disease, Secondary; Tomography, Emission-Computed | 1989 |
Determination and visualization of damage to striatal dopaminergic terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism by [18F]-labeled 6-fluoro-L-dopa and positron emission tomography.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dihydroxyphenylalanine; Macaca mulatta; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Tomography, Emission-Computed | 1987 |